The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWeir Group Regulatory News (WEIR)

Share Price Information for Weir Group (WEIR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,010.00
Bid: 2,006.00
Ask: 2,008.00
Change: 43.00 (2.19%)
Spread: 2.00 (0.10%)
Open: 1,981.00
High: 2,014.00
Low: 1,978.00
Prev. Close: 1,967.00
WEIR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Stabilisation Notice

13 Jul 2023 11:59

RNS Number : 9601F
Mizuho International plc
13 July 2023
 

13/07/2023

 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

WEIR Group Plc/The

 

Stabilisation Notice

Mizuho International plc (contact: Syndicate Desk - Maximilian Wegener; telephone: +4969427293155) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

The securities:

Issuer:

WEIR Group Plc/The

Guarantor (if any):

Aggregate nominal amount:

GBP 300m WEIRLN 6 ⅞ 06/14/28

Description:

Senior, Unsecured, RegS Bearer Notes due in 2028

Offer price:

99.753

Other offer terms:

Stabilisation: Not carried out

Stabilising Manager(s):

Mizuho International plc (Stabilisation Coordinator)

Citigroup Global Markets Ltd

JP Morgan SE

HSBC

 

Stabilisation period expected to start on:

7th of June 2023

Stabilisation period expected to end no later than:

13th July 2023 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

[5% of the aggregate nominal amount stated above.]

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is only directed at, and the securities are only available to, persons having professional experience in matters related to investments and high net worth companies and other persons to whom article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 applies and should not be acted on by others.

To the extent that the offer of the securities is made in any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the date of publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or, where appropriate, published in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), the offer is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive or has been or will be made otherwise in circumstances that do not require the Issuer to publish a prospectus pursuant to the Prospectus Directive.

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

END

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STARJMMTMTABBJJ
Date   Source Headline
25th Apr 20244:06 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Update
15th Apr 20245:21 pmRNSDirector/PDMR Shareholding
15th Apr 20244:28 pmRNSDirector/PDMR Shareholding
15th Apr 20244:19 pmRNSDirector/PDMR Shareholding
15th Apr 20244:18 pmRNSDirector/PDMR Shareholding
10th Apr 20243:18 pmRNSDirector/PDMR Shareholding
10th Apr 20242:14 pmRNSDirector/PDMR Shareholding
10th Apr 20242:11 pmRNSDirector/PDMR Shareholding
5th Apr 202411:30 amRNSHolding(s) in Company
21st Mar 202410:44 amRNS2023 Annual Report and 2024 Annual General Meeting
13th Mar 202410:31 amRNSWeir opens new foundry in China
7th Mar 202411:04 amRNSHolding(s) in Company
29th Feb 20247:00 amRNSFull Year Results
27th Feb 20249:47 amRNSDirectorate Change
7th Feb 20248:48 amRNSHolding(s) in Company
6th Feb 20248:13 amRNSWeir achieves ‘A’ score from CDP
31st Jan 20248:07 amRNSDirectorate Change
19th Dec 202310:29 amRNSNew Board Committee and Board Changes
6th Dec 20237:00 amRNSWeir announces 2026 operating margin target of 20%
5th Dec 20233:09 pmRNSDirectorate Change
4th Dec 20231:30 pmRNSWeir study on energy in mining
23rd Nov 20237:00 amRNSWeir acquires SentianAI
14th Nov 20239:54 amRNSDirector/PDMR Shareholding
7th Nov 20239:04 amRNSDirector/PDMR Shareholding
3rd Nov 20233:51 pmRNSHolding(s) in Company
3rd Nov 20233:51 pmRNSHolding(s) in Company
1st Nov 20237:01 amRNSAppointment of Chief Financial Officer
1st Nov 20237:00 amRNSQ3 Trading Update
26th Oct 20231:55 pmRNSHolding(s) in Company
24th Oct 20238:39 amRNSDirectorate Change
2nd Oct 20237:00 amRNSCapital Markets Event – 6 December 2023
18th Aug 20235:13 pmRNSDirector/PDMR Shareholding
18th Aug 20235:00 pmRNSHolding(s) in Company
18th Aug 20232:44 pmRNSDirector/PDMR Shareholding
18th Aug 20232:30 pmRNSDirector/PDMR Shareholding
1st Aug 20237:00 amRNSHalf-year Report
31st Jul 20232:19 pmRNSTotal Voting Rights
28th Jul 20234:45 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSDirectorate change
27th Jul 20237:00 amRNSAppointment of John Heasley as Finance Director
13th Jul 202311:59 amRNSStabilisation Notice
30th Jun 20233:51 pmRNSTotal Voting Rights
14th Jun 20232:31 pmRNSHolding(s) in Company
12th Jun 20232:50 pmRNSDirector / PDMR Shareholding
8th Jun 20237:00 amRNSPricing of Sustainability-Linked Notes
7th Jun 202311:35 amRNSDirector/PDMR Shareholding
7th Jun 20239:20 amRNSStabilisation Notice
5th Jun 20238:25 amRNSWeir's commitment recognised in CCLA benchmark
1st Jun 20233:34 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.